Skip Navigation
 
 
 
 
 
 
Geisinger
Phone: 800-275-6401
 
 
 

Faculty Page


Ming Ta Michael Lee, PhD

Investigator II

Associate Director of Geisinger Biobank


LOCATION(S)

Genomic Medicine Institute
100 North Academy Avenue
Danville, PA 17822
Phone: 570-271-6664
Fax: 570-214-7342
mlee2@geisinger.edu

EDUCATION

PhD, University of Camridge, 1998-2002


RESEARCH FOCUS

Genomics, Pharmacogenetics, Orthopaedics, Clinical Trials, Immunology/Auto-immune Disease


EXPERTISE

Human genetics and genomics, Pharmacogenetics, Clinical implementation of pharmacogenetics, genetic study of osteoarthritis


RESEARCH INTERESTS

The main aim of our laboratory is to identify genetic associations with diseases; drug induced adverse events or drug efficacy. It is hoped that the discoveries from our research will identify useful biomarkers which could be used to predict drug-induced adverse events, guide drug use and be used in disease prediction diagnosis. I was involved in the first genome-wide association study on bipolar I disorder in the Han-Chinese population and generating the first methylation profiles for both cartilage and subchondral bone. For Pharmacogenetic studies, the study on warfarin dose requirements, which resulted in the identification the SNP associated with warfarin dose. Our study on lithium treatment response on bipolar patients also identified genetic variants associated with treatment response. In addition genetic variant identification, we also conducted clinical studies evaluating the clinical utilities of the identified variants. I also actively participate in several major international consortium, such as International Warfarin Pharmacogenetic Consortium, International Clopidogrel Pharmacogenetic Consortium, Clinical Pharmacogenetics Implementation Consortium and worked with a group of experts to develop guidelines for pharmacogenetic variants.


RECENT PUBLICATIONS

Saito Y, Stamp LK, Caudle KE, Hershfield MS, McDonagh EM, Callaghan JT, Tassaneeyakul W, Mushiroda T, Kamatani N, Goldspiel BR, Phillips EJ, Klein TE and Lee MTM. (2016). Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update. Clin Pharmacol Ther , 99(1):36-37.   

Zhang Y, Fukui N, Yahata M, Katsuragawa Y, Tashiro T, Ikegawa S, Lee MTM. (2015). Genome-wide DNA methylation profile implicates potential cartilage regeneration at the late stage of knee osteoarthritis. Osteoarthritis Cartilage , pii: S1063-4584(15)01436-3. doi: 10.1016.   

Chou CH, Lee MTM, Song IW, Lu LS, Shen HC, Lee CH, Wu JY, Chen YT, Kraus VB, Wu CC . (2015). Insights into osteoarthritis progression revealed by analyses of both knee tibiofemoral compartments. Osteoarthritis Cartilage , 23(4): 571-580.   

Ko TM, Tsai CY, Chen SY, Chen KS, Yu KH, Chu CS, Huang CM, Wang CR, Weng CT, Yu CL, Hsieh SC, Tsai JC, Lai WT, Tsai WC, Yin GD, Ou TT, Cheng KH, Yen JH, Liou TL, Lin TH, Chen DY, Hsiao PJ, Weng MY, Chen YM, Chen CH, Liu MF, Yen HW, Lee JJ, Kuo MC, Wu CC, Hung SY, Luo SF, Yang YH, Chuang HP, Chou YC, Liao HT, Wang CW, Huang CL, Chang CS, Lee MTM, Chen P, Wong CS, Chen CH, Wu JY, Chen YT, Shen CY. (2015). Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study. BMJ , 351: h4848.   

Chen CH, Lee CS, Lee MTM, Ouyang WC, Chen CC, Chong MY, Wu JY, Tan HK, Lee YC, Chuo LJ, Chiu NY, Tsang HY, Chang TJ, Lung FW, Chiu CH, Chang CH, Chen YS, Hou YM, Chen CC, Lai TJ, Tung CL, Chen CY, Lane HY, Su TP, Feng J, Lin JJ, Chang CJ, Teng PR, Liu CY, Chen CK, Liu IC, Chen JJ, Lu T, Fan CC, Wu CK, Li CF, Wang KH, Wu LS, Peng HL, Chang CP, Lu LS, Chen YT, Cheng AT. (2014). Taiwan Bipolar Cortium. Taiwan Bipolar: Variant GADL1 and response to lithium therapy in bipolar I disorder. N Engl J Med , 370(2): 119-128.   


Additional Links